Abstract:Background: A vaccine for enterovirus 71 (EV71) is needed to address the high burden of disease associated with infection. We assessed the efficacy, safety, immunogenicity, antibody persistence, and immunological correlates of an inactivated alum-adjuvant EV71 vaccine. Methods: We did a randomised, double-blind, placebo-controlled, phase 3 trial. Healthy children aged 6-35 months from four centres in China were randomly assigned (1:1) to receive vaccine or alum-adjuvant placebo at day 0 and 28, according to a randomisation list (block size 30) generated by an independent statistician. Investigators and participants and their guardians were masked to the assignment. Primary endpoints were EV71-associated hand, foot, and mouth disease (HFMD) and EV71-associated disease during the surveillance period from day 56 to month 14, analysed in the per-protocol population. This study is registered with ClinicalTrials.gov, number NCT01508247. Findings: 10,245 participants were enrolled and assigned: 5120 to vaccine versus 5125 to placebo. 4907 (with three cases of EV71-associated HFMD and eight cases of EV71-associated disease) versus 4939 (with 30 cases of EV71-associated HFMD and 41 cases of EV71-associated disease) were included in the primary efficacy analysis. Vaccine efficacy was 90·0% (95% CI 67·1-96·9) against EV71-associated HFMD (p=0·0001) and 80·4% (95% CI 58·2-90·8) against EV71-associated disease (p<0·0001). Serious adverse events were reported by 62 of 5117 (1·2%) participants in the vaccine group versus 75 of 5123 (1·5%) in the placebo group (p=0·27). Adverse events occurred in 3644 (71·2%) versus 3603 (70·3%; p=0·33). Interpretation: EV71 vaccine provides high efficacy, satisfactory safety, and sustained immunogenicity. Funding: China's 12-5 National Major Infectious Disease Program, Beijing Vigoo Biological.

Alumina-encapsulated vaccine formulation with improved thermostability and immunogenicity.

Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018TM Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen

COVID‐19 Vaccines: Particulate Alum via Pickering Emulsion for an Enhanced COVID‐19 Vaccine Adjuvant (Adv. Mater. 40/2020)

Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity

A Self-Assembling Nanoparticle: Implications for the Development of Thermostable Vaccine Candidates.

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Robust Vaccine Formulation Produced by Assembling a Hybrid Coating of Polyethyleneimine-Silica.

Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study

Self-assembled aluminum oxyhydroxide nanorices with superior suspension stability for vaccine adjuvant

Alum: An Old Dog With New Tricks

Engineered immunogen binding to alum adjuvant enhances humoral immunity

Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier

Rational Design of Thermostable Vaccines by Engineered Peptide-Induced Virus Self-Biomineralization under Physiological Conditions

Engineering aluminum hydroxyphosphate nanoparticles with well-controlled surface property to enhance humoral immune responses as vaccine adjuvants

Conformation-Stabilized Amorphous Nanocoating for Rational Design of Long-Term Thermostable Viral Vaccines

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8 + T Cell Responses

Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines

The aluminum nanoparticle-encircled SQ-in-water emulsions (ANSWE) as a vaccine adjuvant-delivery system (VADS) for developing robust mucosal subunit vaccines

Nano selenium-enriched probiotic Lactobacillus enhances alum adjuvanticity and promotes antigen-specific systemic and mucosal immunity

Mechanistic elucidation of freezing-induced surface decomposition of aluminum oxyhydroxide adjuvant

Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine